Brainstorm announces the publication of preclinical data highlighting the potential of a nurown® derived exosome-based treatment for covid-19 ards

New york, jan. 20, 2021 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the peer-reviewed publication of a preclinical study in the journal stem cell and research therapy....
BCLI Ratings Summary
BCLI Quant Ranking